Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Large Growth in Short Interest
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Large Growth in Short Interest
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 758,600 shares, a growth of 58.5% from the October 15th total of 478,500 shares. Based on an average trading volume of 12,300,000 shares, the short-interest ratio is currently 0.1 days. Approximately 10.1% of the company's shares are sold short.
光明之心生物科學公司(納斯達克：毒品獲得評級)是空頭股數在10月份實現顯著增長的接受者。截至10月31日，空頭股數共有75.86萬股，比10月15日的47.85萬股增長了58.5%。以12,300,000股的平均成交量計算，目前短息比為0.1天。該公司約10.1%的股票被賣空。
Bright Minds Biosciences Price Performance
Bright Minds生物科學的價格表現
NASDAQ DRUG traded up $0.07 during mid-day trading on Friday, reaching $1.12. 404,034 shares of the stock were exchanged, compared to its average volume of 1,332,820. Bright Minds Biosciences has a one year low of $0.75 and a one year high of $8.30. The stock has a 50 day simple moving average of $1.19 and a 200-day simple moving average of $1.13.
納斯達克藥品在週五午盤交易中上漲0.07美元，達到1.12美元。該股成交量為404,034股，而平均成交量為1,332,820股。Bright Minds Biosciences的一年低點為0.75美元，一年高位為8.30美元。該股的50日簡單移動均線切入位在1.19美元，200日簡單移動均線切入位在1.13美元。
Bright Minds Biosciences (NASDAQ:DRUG – Get Rating) last announced its earnings results on Friday, August 12th. The company reported ($0.17) earnings per share for the quarter.
光明心靈生物科學(納斯達克：藥物獲得評級)最近一次公佈財報是在8月12日(星期五)。該公司公佈了本季度每股收益(0.17美元)。
Hedge Funds Weigh In On Bright Minds Biosciences
對衝基金對Bright Minds生物科學的看法
About Bright Minds Biosciences
關於Bright Minds生物科學
(Get Rating)
(獲取評級)
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家臨牀前生物科學公司，開發5-羥色胺(5-HT)藥物，以改善嚴重和改變生活的疾病患者的生活。該公司的選擇性5-羥色胺受體激動劑組合包括5-HT2C、5-HT2A和5-HT2C/A，用於治療癲癇、疼痛和神經精神病學。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- 免費獲取StockNews.com關於Bright Minds生物科學(藥物)的研究報告
- 標準普爾500指數成分股DexCom將進一步上漲，收益增長
- MarketBeat：回顧中的一週11/7-11/11
- 油價是股市拋售尚未結束的一個令人信服的原因
- 中盤Neurocrine生物科學是井噴後的第三季度報告嗎？
- 六面旗幟是一種你不想被困住的旅程
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bright Minds Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。